论文部分内容阅读
2004年12月9日--中国医药分销市场对外资开放的前两天,湖北九州通集团董事局主席刘宝林与日本株式会社冈村制作所签署了新建三个医药物流配送中心的合同。以此为起点,3-5年内,九州通将在全国建立15个大型物流中心以及围绕这些大型物流中心的100个区域性配送中心。九州通这艘巨舰再次启航,目标当然是成为医药流通领域名副其实的“航母”。按照刘宝林的理解,这个“名副其实”的含义至少是:实现销售收入300亿元,占据中国医药商业10％以上的市场份额。
December 9, 2004 - Two days before the opening up of the pharmaceutical distribution market to foreign investment, Liu Baolin, chairman of the board of Hubei Kyushu Group, and Okamura Co., Ltd. of Japan Co., Ltd. signed a contract to establish three new pharmaceutical distribution centers. Using this as a starting point, Kyushu will establish 15 large-scale logistics centers nationwide and 100 regional distribution centers around these large-scale logistics centers in 3-5 years. Kyushu pass the giant ship set sail again, of course, the goal is to become a true medical circulation “carrier ”. According to Liu Baolin’s understanding, this “worthy of the name ” means at least: to achieve sales revenue of 30 billion yuan, accounting for more than 10% of China’s pharmaceutical business market share.